Clinical Trials Browser

Unknown × pembrolizumab × Other solid neoplasm × Clear all

NCT05311618 2024-04-01

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Phase 1 Unknown

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04294576 2023-11-09

FIH

Phase 1 Unknown

Other solid neoplasm

Locally Advanced/Metastatic Solid Tumors

NCT03654833 2023-03-14

MiST

Phase 2 Unknown

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05035381 2021-09-05

PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer

Phase 2 Unknown

GastrointestinalOther solid neoplasm

MSI-H Advanced Colorectal Cancer

NCT04866485 2021-04-29

A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody

Phase 1 Unknown

Other solid neoplasm

Solid Tumor

NCT04699643 2021-01-07

FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors

Phase 1/2 Unknown

Other solid neoplasm

Advanced Solid Tumors

NCT03975036 2019-06-05

Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody

Phase 2/3 Unknown

Other solid neoplasm

Advanced Solid Tumor

NCT02758587 2018-03-19

Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)

Phase 1/2 Unknown

GastrointestinalOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Pancreatic Neoplasms